Galectin-9, a pro-survival factor inducing immunosuppression, leukemic cell transformation and expansion.
Mol Biol Rep
; 51(1): 571, 2024 Apr 25.
Article
en En
| MEDLINE
| ID: mdl-38662155
ABSTRACT
Leukemia is a malignancy of the bone marrow and blood originating from self-renewing cancerous immature blast cells or transformed leukocytes. Despite improvements in treatments, leukemia remains still a serious disease with poor prognosis because of disease heterogeneity, drug resistance and relapse. There is emerging evidence that differentially expression of co-signaling molecules play a critical role in tumor immune evasion. Galectin-9 (Gal-9) is one of the key proteins that leukemic cells express, secrete, and use to proliferate, self-renew, and survive. It also suppresses host immune responses controlled by T and NK cells, enabling leukemic cells to evade immune surveillance. The present review provides the molecular mechanisms of Gal-9-induced immune evasion in leukemia. Understanding the complex immune evasion machinery driven by Gal-9 expressing leukemic cells will enable the identification of novel therapeutic strategies for efficient immunotherapy in leukemic patients. Combined treatment approaches targeting T-cell immunoglobulin and mucin domain-3 (Tim-3)/Gal-9 and other immune checkpoint pathways can be considered, which may enhance the efficacy of host effector cells to attack leukemic cells.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Leucemia
/
Transformación Celular Neoplásica
/
Galectinas
/
Receptor 2 Celular del Virus de la Hepatitis A
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Mol Biol Rep
/
Mol. Biol. reports
/
Molecular biology reports
Año:
2024
Tipo del documento:
Article
País de afiliación:
Turquía